Krishnan Viswanadhan Sells 2,959 Shares of Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Krishnan Viswanadhan sold 2,959 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the transaction, the insider owned 5,141 shares of the company’s stock, valued at $142,919.80. This trade represents a 36.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Agios Pharmaceuticals Price Performance

Shares of AGIO traded up $1.06 on Monday, hitting $28.53. The company’s stock had a trading volume of 779,690 shares, compared to its average volume of 914,252. The company has a market capitalization of $1.67 billion, a PE ratio of -4.01 and a beta of 0.89. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The company has a 50 day moving average price of $28.05 and a 200 day moving average price of $33.22.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Royal Bank Of Canada cut Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $57.00 to $28.00 in a report on Wednesday, November 19th. Leerink Partners lifted their price target on Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, December 26th. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Truist Financial increased their price objective on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, January 6th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $40.67.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AGIO. T. Rowe Price Investment Management Inc. bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $25,000. Assetmark Inc. lifted its stake in shares of Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 362 shares during the period. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the first quarter valued at about $40,000. First Horizon Corp bought a new position in Agios Pharmaceuticals in the third quarter valued at about $45,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Agios Pharmaceuticals in the fourth quarter worth about $49,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.